Hematology Analyzers Market Segmentation:
Product Type Segment Analysis
The 3-part differential hematology analyzer segment is anticipated to acquire a remarkable market share by 2036, attributed to its growing popularity in terms of cost-effectiveness and compatibility with smaller healthcare settings. The simple design of the medical device makes the costs lower compared to a range of other types of hematology analyzers. The low price, compact size, simple design, and capability to perform rapid testing attract smaller clinics and laboratories to adopt the 3-part differential hematology analyzers significantly. Numerous key players are also engaged in the development of 3-part differential hematology analyzers, influencing the dominance of the segment. For example, in April 2022, Sysmex Europe launched XQ-320, an automated 3-part differential hematology analyzer. In a small bench space, the device can be used using a small sample volume. Sysmex Corporation also expanded the production of the automated medical machine in India in response to the Make in India policy.
Application Segment Analysis
The complete blood count (CBC) segment is estimated to hold a significant market share during the projection timeline, due to the growing prevalence of chronic diseases. This can fuel the adoption of the hematology analyzers to perform the CBC test so that blood cells, platelets, hemoglobin, and white blood cells amounts and sizes can be measured effectively.
Rising deaths caused by different chronic diseases are driving the need for early disease detection and prevention. A report by the World Health Organization, published in August 2024, states that ischemic heart diseases, stroke, chronic obstructive pulmonary disease, lower respiratory infection, lung cancer, bronchus, trachea, alzheimer's disease, dementia, diabetes mellitus, kidney diseases, and tuberculosis were among the 7 of the 10 leading causes of death in 2021. The growing need for early disease detection and prevention is expected to boost the consumption of hematology analyzers to make CBC testing automated, influencing the dominance of the segment in the upcoming financial years.
Statistics on Deaths Caused by Chronic Diseases from 2020 to 2021
|
Causes |
Death counts in 2021/percentage increases in 2021 since 2000 |
|
Ischaemic heart disease |
9.1 million |
|
Stroke |
10% |
|
Obstructive pulmonary disease |
5% |
|
Lower respiratory infections |
2.5 million |
|
Trachea, bronchus, and lung cancers |
1.9 million |
|
Alzheimer’s disease and other forms of dementia |
1.8 million |
|
Diabetes |
95% |
|
Kidney diseases |
95% |
Source: WHO
Automation Level Segment Analysis
The fully automated hematology analyzers segment is projected to account for an extensive market share by the end of 2036, owing to the growing popularity of the advanced medical devices in enhancing diagnostic capabilities in different healthcare settings. The use of cytometry and electrical impedance technology enabled fully automated hematology analyzers not only to help in increasing accuracy in cell counting and analysis but also to obtain quicker outcomes, owing to the high-throughput capabilities. The market accessibility of fully automated hematology analyzers is also growing with the consistency of key players in the development of automated medical devices. For instance, in April 2024, HORIBA Medical launched HELO 2.0, a fully automated and high-throughput hematology analyzer approved by CE-IVDR.
Our in-depth analysis of the market includes the following segments:
|
Segments |
Subsegments |
|
Product Type |
|
|
Modality |
|
|
Application |
|
|
Automation level |
|
|
End use |
|
